Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 24 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018.
- 08 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 May 2015 New trial record